Investment commentary
By Adam Feuerstein
Excerpt-
BOSTON (TheStreet) -- Gilead Sciences(GILD) has drawn first blood from Abbott Labs(ABT) (but just barely) in the battle for hepatitis C pill supremacy.
Twelve weeks of treatment with two Gilead drugs plus ribavirin yielded an interim cure rate of 100% in treatment-naive hepatitis C patients.
A 12-week regimen consisting of three Abbott drugs plus the immune system booster ribavirin demonstrated a final cure rate of 97% of treatment-naive hepatitis C patients and 93% of "null" responders -- the hardest-to-treat patients because they've failed previous therapy.
Hepatitis C researchers, with investors tagging along, are gathering in Boston at the Liver Meeting, the annual conference sponsored by the American Association for the Study of Liver Disease. The most important data presentations over the next four days will focus on the race to develop new pills, which when used in various combinations, can replace the traditional injections long required to treat and cure hepatitis C......
Continue Reading @ The Street
-- Reported by Adam Feuerstein in Boston.
Read previous and future articles by Adam Feuerstein here....
The race is on to develop new, all-oral hepatitis C therapies to replace the need for injections.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies
No comments:
Post a Comment